Clearmind converts $1.045M notes into 885,000 shares; MEAI patent

Clearmind Medicine Inc. (CMND) furnished a Form 6-K reporting balance-sheet activity and an IP update.

Rhea-AI Filing Summary

Clearmind Medicine Inc. (CMND) furnished a Form 6-K reporting balance-sheet activity and an IP update. The company disclosed that on October 30–31, 2025, an aggregate of $1,045,062 of outstanding amounts due under previously issued convertible promissory notes was converted into 885,000 common shares. This reduces note balances while increasing the equity base.

The filing also attaches a press release announcing the publication of a U.S. patent application for its non-hallucinogenic neuroplastogen MEAI therapy aimed at cocaine addiction. Additionally, the Form 6-K and the first three paragraphs of the press release are incorporated by reference into the company’s effective shelf and equity compensation registration statements (Form F-3 File Nos. 333-275991, 333-270859, 333-273293; Form S-8 File No. 333-283695).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CMND disclose in this Form 6-K?

It reported the conversion of $1,045,062 of note balances into 885,000 common shares on October 30–31, 2025, and attached a patent-related press release.

How many CMND shares were issued in the note conversion?

An aggregate of 885,000 common shares were issued against $1,045,062 of outstanding note amounts.

What intellectual property update did CMND include?

A press release on the publication of a U.S. patent application for its MEAI non-hallucinogenic neuroplastogen therapy targeting cocaine addiction.

Which CMND registration statements incorporate this 6-K by reference?

Form F-3 333-275991, 333-270859, 333-273293 and Form S-8 333-283695.

When did the CMND note conversions occur?

On October 30, 2025 and October 31, 2025.

What is MEAI in CMND’s update?

MEAI is described as a non-hallucinogenic neuroplastogen therapy under a U.S. patent application, aimed at treating cocaine addiction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/31/2025 - 08:37 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: October 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is Clearmind Medicine Inc.’s (the “Company”) press release issued on October 31, 2025, titled “Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy”.

In addition, as previously announced, on September 17, 2025, the Company entered into a definitive securities purchase agreements with investors pursuant to which the Company shall issue and sell, from time to time, convertible promissory notes (the “Notes”) in the aggregate principal amount of up to $10,000,000. On October 30, 2025 and October 31, 2025, an aggregate of $1,045,062 of outstanding amounts due under the Notes were converted into 885,000 of the Company’s common shares.

This Form 6-K and the first three paragraphs of the press release attached to this Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File Nos. 333-275991, 333-270859, 333-273293) and Form S-8 (File No. 333-283695), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Advances Fight Against Cocaine Addiction with Publication of U.S. Patent Application for Its Non-Hallucinogenic Neuroplastogen MEAI Therapy”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: October 31, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3